查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108329

表觀遺傳學市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶、解決方案和階段分類

Epigenetics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球表觀遺傳學市場預計將從2025年的20億美元成長到2035年的60億美元，複合年成長率（CAGR）為11.7%。這一成長主要得益於個人化醫療的進步、表觀遺傳學研究經費的增加以及癌症和其他慢性疾病盛行率的上升，這些因素都推動了對錶觀遺傳療法和診斷的需求。表觀遺傳學市場集中度適中，DNA甲基化和組蛋白修飾是主要的技術細分領域。腫瘤學仍然是主要的應用領域，這得益於心血管疾病、代謝性疾病、神經系統疾病和其他慢性疾病研究的持續深入。市場成長的驅動力來自對精準醫療、生物標記發現和先進基因組學研究日益成長的需求。製藥公司、生技公司和學術機構對表觀遺傳學研究工具、試劑和分析平台的應用持續成長。競爭主要體現在持續的創新、策略聯盟、研究合作和收購，這些措施旨在推動表觀遺傳療法的發展、提高診斷能力、拓展產品系列併增強全球市場地位。

依類型分類，表觀遺傳學市場可分為DNA甲基化、組蛋白修飾、RNA表觀遺傳學、染色質重塑、非編碼RNA及其他。其中，DNA甲基化因其在癌症研究、生物標記發現和疾病診斷中的廣泛應用而佔較大的市場佔有率。 DNA甲基化分析被廣泛用於了解與各種慢性疾病相關的基因表現變化，並已成為製藥業和學術研究的重點領域。同時，隨著精準醫療和先進基因組學研究投入的不斷增加，RNA表觀遺傳學和染色質重塑也發展迅速，從而推動了表觀遺傳學市場的整體擴張。

市場區隔
類型 DNA甲基化、組蛋白修飾、RNA表觀遺傳學、染色質重塑、非編碼RNA等。
產品 試劑、試劑盒、儀器、酵素、抗體及其他
服務 表觀遺傳定定序、甲基化分析、染色質分析、生物資訊、諮詢等。
科技 次世代定序、聚合酵素鏈鎖反應、質譜分析、染色質免疫沉澱分析法、微陣列等。
成分 軟體、硬體、耗材及其他
目的 腫瘤學、心血管疾病、代謝性疾病、神經退化性疾病、免疫學、感染疾病等。
流程 檢體預處理、資料分析、驗證及其他相關任務。
最終用戶 學術和研究機構、製藥公司、生物技術公司、受託研究機構（CRO）、診斷測試實驗室等。
解決方案 表觀遺傳生物標記、表觀遺傳編輯及其他
步 研究、臨床試驗、商業化等

從應用領域來看，表觀遺傳學市場可細分為腫瘤學、心血管疾病、代謝性疾病、神經退化性疾病、免疫學、感染疾病及其他領域。其中，腫瘤學領域是推動市場成長的主要動力，因為表觀遺傳學技術在癌症診斷、預後和標靶治療研發中的應用日益廣泛。全球癌症發生率的上升以及對個人化醫療投入的不斷成長，持續推動腫瘤學領域對錶觀遺傳學研究的需求。此外，隨著研究人員闡明表觀遺傳機制以識別新的治療標靶並改善疾病管理，表觀遺傳學在神經退化性疾病疾病和代謝性疾病領域的應用也在不斷擴展，進一步促進了市場成長。

區域概覽

北美在表觀遺傳學市場佔最大佔有率，這主要得益於廣泛的生物醫學研究、精準醫療的日益普及以及對基因組學和腫瘤學的大力投入。該地區匯聚了許多領先的生物技術公司、製藥公司和學術研究機構，它們正針對癌症、神經系統疾病和罕見疾病進行先進的表觀遺傳學研究。大量的政府資助、先進的定序技術和完善的實驗室基礎設施為持續創新提供了支援。對生物標記發現、藥物研發和伴隨診斷日益成長的需求，進一步推動了市場成長，並鞏固了北美在區域市場的領先地位。

亞太地區預計將成為表觀遺傳學市場成長最快的地區，這主要得益於生物醫學研究的拓展、醫療保健投資的增加以及精準醫療意識的提高。中國、日本、韓國和印度等國家正在基因組學研究、分子診斷和癌症研究計畫方面投入大量資金。慢性病盛行率的上升、製藥業研發投入的增加以及與國際研究機構合作的加強，都在加速市場發展。實驗室基礎設施的改善、政府的支持措施以及對個人化醫療解決方案日益成長的需求，預計將繼續支持該地區的快速成長。

主要趨勢和促進因素

多體學技術的整合正在推動表觀遺傳學研究：

表觀表觀基因、基因組學、轉錄組學和蛋白​​質組學的日益融合是表觀遺傳學市場的一大趨勢。研究人員正利用多體學方法，以更深入地了解基因表現調控、疾病進展和治療反應。定序技術、生物資訊學和人工智慧的進步正在提高癌症、神經系統疾病和慢性疾病表觀遺傳生物標記識別的準確性。這些創新正在支持個人化醫療的發展，並加速新型診斷工具和標靶治療策略的發現。

癌症和慢性病發病率的上升正在推動市場成長：

癌症、心血管疾病、神經系統疾病和其他慢性疾病發生率的上升是表觀遺傳學市場的重要促進因素。人們對表觀遺傳修飾在疾病發展中的作用認知不斷提高，推動了對先進研究工具、生物標記和診斷技術的需求。藥物研發的拓展、精準醫療投資的增加、政府對生命科學研究投入的加大以及技術的持續進步，都進一步促進了表觀遺傳學解決方案在全球範圍內的應用。

目錄

第1章：摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • DNA甲基化
    • 組蛋白修飾
    • RNA表觀遺傳學
    • 染色質重塑
    • 非編碼RNA
    • 其他
  • 市場規模及預測：依產品分類
    • 試劑
    • 成套工具
    • 裝置
    • 酵素
    • 抗體
    • 其他
  • 市場規模及預測：依服務分類
    • 表觀遺傳定序
    • 甲基化分析
    • 染色質分析
    • 生物資訊學
    • 諮詢
    • 其他
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 質譜分析
    • 染色質免疫沉澱分析法
    • 微陣列
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 代謝性疾病
    • 神經退化性疾病
    • 免疫學
    • 感染疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 學術研究機構
    • 製藥公司
    • 生技公司
    • 受託研究機構
    • 診斷檢查室
    • 其他
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 消耗品
    • 其他
  • 市場規模及預測：依製程分類
    • 樣品製備
    • 數據分析
    • 驗證
    • 其他
  • 市場規模及預測：按解決方案分類
    • 表觀遺傳生物標記
    • 表觀遺傳編輯
    • 其他
  • 市場規模及預測：依階段分類
    • 調查
    • 臨床試驗
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • Qiagen
  • Merck KGaA
  • Abcam
  • Zymo Research
  • PerkinElmer
  • Bio-Rad Laboratories
  • Agilent Technologies
  • Diagenode
  • New England Biolabs
  • Active Motif
  • EpiGentek
  • Roche
  • Pacific Biosciences
  • SomaLogic
  • Oxford Nanopore Technologies
  • Takara Bio
  • Promega Corporation
  • Horizon Discovery

第9章 關於我們

簡介目錄
Product Code: GIS32998

The global epigenetics market is projected to grow from $2.0 billion in 2025 to $6.0 billion by 2035, at a compound annual growth rate (CAGR) of 11.7%. This growth is driven by advancements in personalized medicine, increased funding for epigenetics research, and the rising prevalence of cancer and other chronic diseases, which are boosting the demand for epigenetic therapies and diagnostics. The Epigenetics Market is moderately consolidated, with DNA methylation and histone modification representing the leading technology segments. Oncology remains the primary application area, supported by expanding research in cardiovascular, metabolic, neurological, and other chronic diseases. Market growth is fueled by increasing demand for precision medicine, biomarker discovery, and advanced genomic research. Adoption of epigenetic research tools, reagents, and analytical platforms continues to rise across pharmaceutical companies, biotechnology firms, and academic institutions. Competition is driven by continuous innovation, strategic partnerships, research collaborations, and acquisitions aimed at advancing epigenetic therapeutics, improving diagnostic capabilities, expanding product portfolios, and strengthening global market presence.

Based on Type, the epigenetics market is segmented into DNA Methylation, Histone Modification, RNA Epigenetics, Chromatin Remodeling, Non-coding RNA, and Others. Among these, DNA Methylation holds a significant market share owing to its widespread application in cancer research, biomarker discovery, and disease diagnostics. DNA methylation analysis is extensively used to understand gene expression changes associated with various chronic diseases, making it a key focus area for pharmaceutical and academic research. Meanwhile, RNA epigenetics and chromatin remodeling are gaining momentum due to increasing investments in precision medicine and advanced genomic research, supporting the overall expansion of the epigenetics market.

Market Segmentation
TypeDNA Methylation, Histone Modification, RNA Epigenetics, Chromatin Remodeling, Non-coding RNA, Others
ProductReagents, Kits, Instruments, Enzymes, Antibodies, Others
ServicesEpigenetic Sequencing, Methylation Analysis, Chromatin Analysis, Bioinformatics, Consulting, Others
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, Chromatin Immunoprecipitation, Microarray, Others
ComponentSoftware, Hardware, Consumables, Others
ApplicationOncology, Cardiovascular Diseases, Metabolic Diseases, Neurodegenerative Diseases, Immunology, Infectious Diseases, Others
ProcessSample Preparation, Data Analysis, Validation, Others
End UserAcademic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Diagnostic Laboratories, Others
SolutionsEpigenetic Biomarkers, Epigenetic Editing, Others
StageResearch, Clinical Trials, Commercialization, Others

Based on Application, the epigenetics market is segmented into Oncology, Cardiovascular Diseases, Metabolic Diseases, Neurodegenerative Diseases, Immunology, Infectious Diseases, and Others. Among these, Oncology dominates the market due to the growing use of epigenetic technologies in cancer diagnosis, prognosis, and targeted therapy development. The increasing prevalence of cancer worldwide and rising investments in personalized medicine continue to drive demand for epigenetic research in oncology. Additionally, applications in neurodegenerative and metabolic diseases are expanding as researchers explore epigenetic mechanisms to identify novel therapeutic targets and improve disease management, further contributing to market growth.

Geographical Overview

North America holds the largest share of the epigenetics market due to extensive biomedical research, increasing adoption of precision medicine, and strong investments in genomics and oncology. The region is home to leading biotechnology companies, pharmaceutical firms, and academic research institutions conducting advanced epigenetic studies for cancer, neurological disorders, and rare diseases. Significant government funding, advanced sequencing technologies, and well-developed laboratory infrastructure support continuous innovation. Rising demand for biomarker discovery, drug development, and companion diagnostics further contributes to market growth, reinforcing North America's position as the leading regional market.

Asia-Pacific is projected to be the fastest-growing market for epigenetics due to expanding biomedical research, increasing healthcare investments, and growing awareness of precision medicine. Countries such as China, Japan, South Korea, and India are investing heavily in genomics research, molecular diagnostics, and cancer research programs. Rising prevalence of chronic diseases, expanding pharmaceutical R&D, and increasing collaborations with international research organizations are accelerating market development. Improvements in laboratory infrastructure, supportive government initiatives, and growing demand for personalized healthcare solutions are expected to sustain rapid regional growth.

Key Trends and Drivers

Integration of Multi-Omics Technologies Is Advancing Epigenetics Research:

The increasing integration of epigenomics with genomics, transcriptomics, and proteomics is a major trend in the epigenetics market. Researchers are utilizing multi-omics approaches to better understand gene regulation, disease progression, and therapeutic response. Advances in sequencing technologies, bioinformatics, and artificial intelligence are improving the identification of epigenetic biomarkers for cancer, neurological disorders, and chronic diseases. These innovations are supporting personalized medicine initiatives and accelerating the discovery of novel diagnostic tools and targeted therapeutic strategies.

Rising Prevalence of Cancer and Chronic Diseases Is Driving the Market Growth:

The growing incidence of cancer, cardiovascular diseases, neurological disorders, and other chronic illnesses is a significant driver of the epigenetics market. Increasing recognition of the role of epigenetic modifications in disease development is driving demand for advanced research tools, biomarkers, and diagnostic technologies. Expanding pharmaceutical research, growing investments in precision medicine, increasing government funding for life science research, and continuous technological advancements are further supporting the adoption of epigenetic solutions worldwide.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 DNA Methylation
    • 4.1.2 Histone Modification
    • 4.1.3 RNA Epigenetics
    • 4.1.4 Chromatin Remodeling
    • 4.1.5 Non-coding RNA
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Kits
    • 4.2.3 Instruments
    • 4.2.4 Enzymes
    • 4.2.5 Antibodies
    • 4.2.6 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Epigenetic Sequencing
    • 4.3.2 Methylation Analysis
    • 4.3.3 Chromatin Analysis
    • 4.3.4 Bioinformatics
    • 4.3.5 Consulting
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Mass Spectrometry
    • 4.4.4 Chromatin Immunoprecipitation
    • 4.4.5 Microarray
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Metabolic Diseases
    • 4.5.4 Neurodegenerative Diseases
    • 4.5.5 Immunology
    • 4.5.6 Infectious Diseases
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Academic and Research Institutes
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Biotechnology Companies
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Diagnostic Laboratories
    • 4.6.6 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
    • 4.7.3 Consumables
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Sample Preparation
    • 4.8.2 Data Analysis
    • 4.8.3 Validation
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Epigenetic Biomarkers
    • 4.9.2 Epigenetic Editing
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Research
    • 4.10.2 Clinical Trials
    • 4.10.3 Commercialization
    • 4.10.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Qiagen
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Merck KGaA
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Abcam
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Zymo Research
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 PerkinElmer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bio-Rad Laboratories
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Agilent Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Diagenode
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 New England Biolabs
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Active Motif
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 EpiGentek
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Roche
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pacific Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 SomaLogic
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Oxford Nanopore Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Takara Bio
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Promega Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Horizon Discovery
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us